Ask AI
ProCE Banner Series

More than a Memory: Advancing Early Diagnosis and Amyloid-Targeted Therapies for Alzheimer's Disease

Early diagnosis and accessibility of treatment options are key to optimal use of amyloid-targeting therapies, allowing patients to receive the greatest benefits in slowing the progression of Alzheimer’s disease. This neurology-focused presentation includes current evidence and expert recommendations for patients with Alzheimer’s disease from the first signs of cognitive decline to individualized treatment selection, including newly available biomarker testing and maintenance therapy.

  AAPA
  | AMA
  | ANCC
Who Should Attend

This activity is intended for neurologists, geriatricians, nurse practitioners, physician associates, psychiatrists, and other healthcare professionals caring for patients with AD.

Topics

Dementia

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, competence, and confidence in optimally applying recent data and practice-changing findings in treating patients with AD.

Target Audience
This activity is intended for neurologists, geriatricians, nurse practitioners, physician associates, psychiatrists, and other healthcare professionals caring for patients with AD.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Integrate current evidence and expert recommendations on biomarker testing to support early detection of Alzheimer’s disease pathology
  • Assess the safety and efficacy of newly approved and investigational treatments for Alzheimer’s disease
  • Define the clinical role of novel and emerging therapies in the evolving AD treatment landscape
  • Translate recent clinical trial findings into practice to expand therapeutic options and enhance patient outcomes
  • Identify key benefits and practical considerations of subcutaneous therapy (e.g., SC lecanemab), including administration timing, autoinjector use, and patient training
  • Implement adherence support strategies for patients receiving SC therapy, addressing barriers like needle anxiety, storage logistics, and self-administration confidence

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

IPCE Credit Designation

A logo for a credit companyAI-generated content may be incorrect.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME for MIPS

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/645130bfd42f3.png

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

In order to fulfill requirements for MIPS improvement activity, participants will need to fill out 2 brief follow-up surveys at 30- and 90-days post-activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Eisai.

Eisai

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191